HIV Infection, Vascular Disease, and Stroke

Abstract

With the transformation of HIV infection into a chronic disease for the majority of patients with access to combination antiretroviral therapy, HIV-infected individuals and their medical providers are facing a new set of challenges, many of which are more typical of an aging population. Accumulating evidence indicates that rates of stroke, like coronary heart disease, may be higher in HIV-infected individuals. This review will discuss the epidemiology of stroke in HIV infection, potential mechanisms underlying the pathogenesis of stroke, vascular risk and cognitive impairment, cardiovascular and stroke risk prediction, and strategies for stroke prevention in this at-risk population, with a focus on HIV-associated cerebrovascular disease in the current era of highly effective combination antiretroviral therapy

Keywords

human immunodeficiency virus infection - stroke - ischemic stroke - cerebrovascular disease - cardiovascular risk - intracerebral hemorrhage

• References

• 1 Lewden C, Chêne G, Morlat P , et al; Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) CO8 APROCO-COPILOTE Study Group; Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) CO3 AQUITAINE Study Group. HIV-infected adults with a CD4 cell count greater than 500 cells/mm³ on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46 (1) 72-77
• 2 Rodger AJ, Lodwick R, Schechter M , et al; INSIGHT SMART, ESPRIT Study Groups. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013; 27 (6) 973-979
• 3 van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F ; ATHENA national observational cohort study. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 2010; 24 (10) 1527-1535
• 4 Hasse B, Ledergerber B, Furrer H , et al; Swiss HIV Cohort Study. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011; 53 (11) 1130-1139
• 5 Mocroft A, Reiss P, Gasiorowski J , et al; EuroSIDA Study Group. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 2010; 55 (2) 262-270
• 6 Klein D, Hurley LB, Quesenberry Jr CP, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?. J Acquir Immune Defic Syndr 2002; 30 (5) 471-477
• 7 Currier JS, Taylor A, Boyd F , et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33 (4) 506-512
• 8 Obel N, Thomsen HF, Kronborg G , et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007; 44 (12) 1625-1631
• 9 Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92 (7) 2506-2512
• 10 Lang S, Mary-Krause M, Cotte L , et al; French Hospital Database on HIV-ANRS CO4. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 2010; 24 (8) 1228-1230
• 11 Freiberg MS, Chang CC, Kuller LH , et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173 (8) 614-622
• 12 Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348 (8) 702-710
• 13 Sabin CA, Ryom L, De Wit S , et al; D:A:D Study Group. Associations between immune depression and cardiovascular events in HIV infection. AIDS 2013; 27 (17) 2735-2748
• 14 d'Arminio A, Sabin CA, Phillips AN , et al; Writing Committee of the D:A:D: Study Group. Cardio- and cerebrovascular events in HIV-infected persons. AIDS 2004; 18 (13) 1811-1817
• 15 Feigin VL, Lawes CMM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009; 8 (4) 355-369
• 16 Norrving B, Kissela B. The global burden of stroke and need for a continuum of care. Neurology 2013; 80 (3) (Suppl. 02) S5-S12
• 17 Wester CW, Koethe JR, Shepherd BE , et al. Non-AIDS-defining events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban setting. AIDS 2011; 25 (12) 1471-1479
• 18 Hirschhorn LR, Kaaya SF, Garrity PS, Chopyak E, Fawzi MCS. Cancer and the 'other' noncommunicable chronic diseases in older people living with HIV/AIDS in resource-limited settings: a challenge to success. AIDS 2012; 26 (Suppl. 01) S65-S75
• 19 Levy RM, Bredesen DE, Rosenblum ML. Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. J Neurosurg 1985; 62 (4) 475-495
• 20 Engstrom JW, Lowenstein DH, Bredesen DE. Cerebral infarctions and transient neurologic deficits associated with acquired immunodeficiency syndrome. Am J Med 1989; 86 (5) 528-532
• 21 Anders KH, Guerra WF, Tomiyasu U, Verity MA, Vinters HV. The neuropathology of AIDS. UCLA experience and review. Am J Pathol 1986; 124 (3) 537-558
• 22 Mizusawa H, Hirano A, Llena JF, Shintaku M. Cerebrovascular lesions in acquired immune deficiency syndrome (AIDS). Acta Neuropathol 1988; 76 (5) 451-457
• 23 Connor MD, Lammie GA, Bell JE, Warlow CP, Simmonds P, Brettle RD. Cerebral infarction in adult AIDS patients: observations from the Edinburgh HIV Autopsy Cohort. Stroke 2000; 31 (9) 2117-2126
• 24 Qureshi AI, Janssen RS, Karon JM , et al. Human immunodeficiency virus infection and stroke in young patients. Arch Neurol 1997; 54 (9) 1150-1153
• 25 Cole JW, Pinto AN, Hebel JR , et al. Acquired immunodeficiency syndrome and the risk of stroke. Stroke 2004; 35 (1) 51-56
• 26 Berger JR, Harris JO, Gregorios J, Norenberg M. Cerebrovascular disease in AIDS: a case-control study. AIDS 1990; 4 (3) 239-244
• 27 Hoffmann M, Berger JR, Nath A, Rayens M. Cerebrovascular disease in young, HIV-infected, black Africans in the KwaZulu Natal province of South Africa. J Neurovirol 2000; 6 (3) 229-236
• 28 Patel VB, Sacoor Z, Francis P, Bill PLA, Bhigjee AI, Connolly C. Ischemic stroke in young HIV-positive patients in Kwazulu-Natal, South Africa. Neurology 2005; 65 (5) 759-761
• 29 Ovbiagele B, Nath A. Increasing incidence of ischemic stroke in patients with HIV infection. Neurology 2011; 76 (5) 444-450
• 30 Rasmussen LD, Engsig FN, Christensen H , et al. Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. AIDS 2011; 25 (13) 1637-1646
• 31 Chow FC, Regan S, Feske S, Meigs JB, Grinspoon SK, Triant VA. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US health care system. J Acquir Immune Defic Syndr 2012; 60 (4) 351-358
• 32 Fitch KV, Srinivasa S, Abbara S , et al. Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. J Infect Dis 2013; 208 (11) 1737-1746
• 33 Boger MS, Bian A, Shintani A , et al. Sex differences in urinary biomarkers of vascular and endothelial function in HIV-infected persons receiving antiretroviral therapy. Antivir Ther 2012; 17 (3) 485-493
• 34 Mateen FJ, Shinohara RT, Carone M , et al; Multicenter AIDS Cohort Study (MACS) Investigators. Neurologic disorders incidence in HIV+ vs HIV- men: Multicenter AIDS Cohort Study, 1996-2011. Neurology 2012; 79 (18) 1873-1880
• 35 Meier A, Chang JJ, Chan ES , et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med 2009; 15 (8) 955-959
• 36 Redfors P, Jood K, Holmegaard L, Rosengren A, Blomstrand C, Jern C. Stroke subtype predicts outcome in young and middle-aged stroke sufferers. Acta Neurol Scand 2012; 126 (5) 329-335
• 37 Mochan A, Modi M, Modi G. Stroke in black South African HIV-positive patients: a prospective analysis. Stroke 2003; 34 (1) 10-15
• 38 Ortiz G, Koch S, Romano JG, Forteza AM, Rabinstein AA. Mechanisms of ischemic stroke in HIV-infected patients. Neurology 2007; 68 (16) 1257-1261
• 39 Corral I, Quereda C, Moreno A , et al. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors. Cerebrovasc Dis 2009; 27 (6) 559-563
• 40 Vinikoor MJ, Napravnik S, Floris-Moore M, Wilson S, Huang DY, Eron JJ. Incidence and clinical features of cerebrovascular disease among HIV-infected adults in the Southeastern United States. AIDS Res Hum Retroviruses 2013; 29 (7) 1068-1074
• 41 Evers S, Nabavi D, Rahmann A, Heese C, Reichelt D, Husstedt I-W. Ischaemic cerebrovascular events in HIV infection: a cohort study. Cerebrovasc Dis 2003; 15 (3) 199-205
• 42 Kristensen B, Malm J, Carlberg B , et al. Epidemiology and etiology of ischemic stroke in young adults aged 18 to 44 years in northern Sweden. Stroke 1997; 28 (9) 1702-1709
• 43 Kittner SJ, Stern BJ, Wozniak M , et al. Cerebral infarction in young adults: the Baltimore-Washington Cooperative Young Stroke Study. Neurology 1998; 50 (4) 890-894
• 44 Adams Jr HP, Kappelle LJ, Biller J , et al. Ischemic stroke in young adults. Experience in 329 patients enrolled in the Iowa Registry of Stroke in Young Adults. Arch Neurol 1995; 52 (5) 491-495
• 45 Maniker AH, Hunt CD. Cerebral aneurysm in the HIV patient: a report of six cases. Surg Neurol 1996; 46 (1) 49-54
• 46 Dubrovsky T, Curless R, Scott G , et al. Cerebral aneurysmal arteriopathy in childhood AIDS. Neurology 1998; 51 (2) 560-565
• 47 Bulsara KR, Raja A, Owen J. HIV and cerebral aneurysms. Neurosurg Rev 2005; 28 (2) 92-95
• 48 Miyamoto S, Hara T, Tabei Y, Honma H, Kondo T, Oka S. Aneurysmal subarachnoid hemorrhage in a patient with human immunodeficiency virus type 1 infection. Case report. Neurol Med Chir (Tokyo) 2006; 46 (7) 348-352
• 49 Ake JA, Erickson JC, Lowry KJ. Cerebral aneurysmal arteriopathy associated with HIV infection in an adult. Clin Infect Dis 2006; 43 (5) e46-e50
• 50 Kossorotoff M, Touzé E, Godon-Hardy S , et al. Cerebral vasculopathy with aneurysm formation in HIV-infected young adults. Neurology 2006; 66 (7) 1121-1122
• 51 Modi G, Ranchod K, Modi M, Mochan A. Human immunodeficiency virus associated intracranial aneurysms: report of three adult patients with an overview of the literature. J Neurol Neurosurg Psychiatry 2008; 79 (1) 44-46
• 52 Goldstein DA, Timpone J, Cupps TR. HIV-associated intracranial aneurysmal vasculopathy in adults. J Rheumatol 2010; 37 (2) 226-233
• 53 Mazzoni P, Chiriboga CA, Millar WS, Rogers A. Intracerebral aneurysms in human immunodeficiency virus infection: case report and literature review. Pediatr Neurol 2000; 23 (3) 252-255
• 54 Martínez-Longoria CA, Morales-Aguirre JJ, Villalobos-Acosta CP, Gómez-Barreto D, Cashat-Cruz M. Occurrence of intracerebral aneurysm in an HIV-infected child: a case report. Pediatr Neurol 2004; 31 (2) 130-132
• 55 Durand M, Sheehy O, Baril JG, LeLorier J, Tremblay CL. Risk of spontaneous intracranial hemorrhage in HIV-infected individuals: a population-based cohort study. J Stroke Cerebrovasc Dis 2013; 22 (7) e34-e41
• 56 Chow FC, Regan S, Feske SF, Meigs J, Grinspoon SK, Triant V. Increased incidence of intracerebral hemorrhage in younger and female HIV-infected individuals in a clinical care cohort. Neurology 2013; 80 (Meeting Abstracts: S38.004)
• 57 Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naïve and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis 2003; 22 (12) 731-736
• 58 Seaberg EC, Muñoz A, Lu M , et al; Multicenter AIDS Cohort Study. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005; 19 (9) 953-960
• 59 Palacios R, Santos J, García A , et al. Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients. HIV Med 2006; 7 (1) 10-15
• 60 De Socio GV, Ricci E, Maggi P , et al; CISAI Study Group. Prevalence, awareness, treatment, and control rate of hypertension in HIV-infected patients: the HIV-HY study. Am J Hypertens 2014; 27 (2) 222-228
• 61 Gutierrez J, Elkind MSV, Marshall RS. Cardiovascular profile and events of US adults 20-49 years with HIV: results from the NHANES 1999-2008. AIDS Care 2013; 25 (11) 1385-1391
• 62 Carr A, Samaras K, Burton S , et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12 (7) F51-F58
• 63 Périard D, Telenti A, Sudre P , et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100 (7) 700-705
• 64 Hadigan C, Meigs JB, Corcoran C , et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32 (1) 130-139
• 65 Tien PC, Schneider MF, Cole SR , et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 2007; 21 (13) 1739-1745
• 66 Brown TT, Cole SR, Li X , et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165 (10) 1179-1184
• 67 De Wit S, Sabin CA, Weber R , et al; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008; 31 (6) 1224-1229
• 68 Friis-Møller N, Weber R, Reiss P , et al; DAD study group. Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17 (8) 1179-1193
• 69 Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav 2010; 14 (4) 824-835
• 70 Lifson AR, Neuhaus J, Arribas JR, van den Berg-Wolf M, Labriola AM, Read TR ; INSIGHT SMART Study Group. Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. Am J Public Health 2010; 100 (10) 1896-1903
• 71 Vance DE, Mugavero M, Willig J, Raper JL, Saag MS. Aging with HIV: a cross-sectional study of comorbidity prevalence and clinical characteristics across decades of life. J Assoc Nurses AIDS Care 2011; 22 (1) 17-25
• 72 Nüesch R, Wang Q, Elzi L , et al; Swiss HIV Cohort Study. Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS). J Acquir Immune Defic Syndr 2013; 62 (4) 396-404
• 73 Hsue PY, Lo JC, Franklin A , et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109 (13) 1603-1608
• 74 Grunfeld C, Delaney JA, Wanke C , et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 2009; 23 (14) 1841-1849
• 75 Maggi P, Lillo A, Perilli F, Maserati R, Chirianni A ; PREVALEAT Group. Colour-Doppler ultrasonography of carotid vessels in patients treated with antiretroviral therapy: a comparative study. AIDS 2004; 18 (7) 1023-1028
• 76 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22 (8) 983-988
• 77 Hsu JC, Li Y, Marcus GM , et al. Atrial fibrillation and atrial flutter in human immunodeficiency virus-infected persons: incidence, risk factors, and association with markers of HIV disease severity. J Am Coll Cardiol 2013; 61 (22) 2288-2295
• 78 Morris JG, Singh S, Fisher M. Testing for inherited thrombophilias in arterial stroke: can it cause more harm than good?. Stroke 2010; 41 (12) 2985-2990
• 79 Mochan A, Modi M, Modi G. Protein S deficiency in HIV associated ischaemic stroke: an epiphenomenon of HIV infection. J Neurol Neurosurg Psychiatry 2005; 76 (10) 1455-1456
• 80 Tipping B, de Villiers L, Wainwright H, Candy S, Bryer A. Stroke in patients with human immunodeficiency virus infection. J Neurol Neurosurg Psychiatry 2007; 78 (12) 1320-1324
• 81 Galrão L, Brites C, Atta ML , et al. Antiphospholipid antibodies in HIV-positive patients. Clin Rheumatol 2007; 26 (11) 1825-1830
• 82 Hadigan C, Meigs JB, Rabe J , et al; Framingham Heart Study. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001; 86 (2) 939-943
• 83 Calabrese LH. Infection with the human immunodeficiency virus type 1 and vascular inflammatory disease. Clin Exp Rheumatol 2004; 22 (6) (Suppl. 36) S87-S93
• 84 Chetty R. Vasculitides associated with HIV infection. J Clin Pathol 2001; 54 (4) 275-278
• 85 Gutierrez J, Glenn M, Isaacson RS, Marr AD, Mash D, Petito C. Thinning of the arterial media layer as a possible preclinical stage in HIV vasculopathy: a pilot study. Stroke 2012; 43 (4) 1156-1158
• 86 Bhagavati S, Choi J. Rapidly progressive cerebrovascular stenosis and recurrent strokes followed by improvement in HIV vasculopathy. Cerebrovasc Dis 2008; 26 (4) 449-452
• 87 Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis 2011; 53 (1) 84-91
• 88 Friis-Møller N, Reiss P, Sabin CA , et al; DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356 (17) 1723-1735
• 89 Worm SW, Sabin C, Weber R , et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201 (3) 318-330
• 90 Sabin CA, Worm SW, Weber R , et al; D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371 (9622) 1417-1426
• 91 Lang S, Mary-Krause M, Cotte L , et al; Clinical Epidemiology Group of the French Hospital Database on HIV. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170 (14) 1228-1238
• 92 Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 2011; 25 (10) 1289-1298
• 93 Worm SW, Kamara DA, Reiss P , et al; D:A:D Study Group. Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke. J Infect Dis 2012; 205 (4) 535-539
• 94 Solages A, Vita JA, Thornton DJ , et al. Endothelial function in HIV-infected persons. Clin Infect Dis 2006; 42 (9) 1325-1332
• 95 Kaplan RC, Kingsley LA, Gange SJ , et al. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 2008; 22 (13) 1615-1624
• 96 Triant VA, Regan S, Lee H, Sax PE, Meigs JB, Grinspoon SK. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr 2010; 55 (5) 615-619
• 97 Lichtenstein KA, Armon C, Buchacz K , et al; HIV Outpatient Study (HOPS) Investigators. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010; 51 (4) 435-447
• 98 Torriani FJ, Komarow L, Parker RA , et al; ACTG 5152s Study Team. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008; 52 (7) 569-576
• 99 Baker JV, Henry WK, Patel P , et al; Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy Investigators. Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort. Clin Infect Dis 2011; 53 (8) 826-835
• 100 Ding X, Andraca-Carrera E, Cooper C , et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr 2012; 61 (4) 441-447
• 101 Bavinger C, Bendavid E, Niehaus K , et al. Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS ONE 2013; 8 (3) e59551
• 102 Monforte Ad, Reiss P, Ryom L , et al. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. AIDS 2013; 27 (3) 407-415
• 103 Libby P, Ridker PM, Hansson GK ; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54 (23) 2129-2138
• 104 Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352 (16) 1685-1695
• 105 Elkind MS, Ramakrishnan P, Moon YP , et al. Infectious burden and risk of stroke: the northern Manhattan study. Arch Neurol 2010; 67 (1) 33-38
• 106 Elkind MS, Luna JM, Moon YP , et al. Infectious burden and carotid plaque thickness: the northern Manhattan study. Stroke 2010; 41 (3) e117-e122
• 107 El-Sadr WM, Lundgren J, Neaton JD , et al; Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355 (22) 2283-2296
• 108 Kuller LH, Tracy R, Belloso W , et al; INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5 (10) e203
• 109 Duprez DA, Neuhaus J, Kuller LH , et al; INSIGHT SMART Study Group. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS ONE 2012; 7 (9) e44454
• 110 Ford ES, Greenwald JH, Richterman AG , et al. . Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS 2010; 24 (10) 1509-1517
• 111 Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009; 51 (3) 268-273
• 112 Kaplan RC, Sinclair E, Landay AL , et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 2011; 203 (4) 452-463
• 113 Burdo TH, Lo J, Abbara S , et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011; 204 (8) 1227-1236
• 114 Hsue PY, Hunt PW, Schnell A , et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009; 23 (9) 1059-1067
• 115 Hunt PW, Brenchley J, Sinclair E , et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197 (1) 126-133
• 116 Gorelick PB. Risk factors for vascular dementia and Alzheimer disease. Stroke 2004; 35 (11) (Suppl. 01) 2620-2622
• 117 Gorelick PB, Scuteri A, Black SE , et al; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42 (9) 2672-2713
• 118 Heaton RK, Clifford DB, Franklin Jr DR , et al; CHARTER Group. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75 (23) 2087-2096
• 119 Heaton RK, Franklin DR, Ellis RJ , et al; CHARTER Group; HNRC Group. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011; 17 (1) 3-16
• 120 Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol 2004; 10 (6) 350-357
• 121 Tozzi V, Balestra P, Murri R , et al. Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART. Int J STD AIDS 2004; 15 (4) 254-259
• 122 Valcour VG, Shikuma CM, Shiramizu BT , et al. Diabetes, insulin resistance, and dementia among HIV-1-infected patients. J Acquir Immune Defic Syndr 2005; 38 (1) 31-36
• 123 Valcour VG, Sacktor NC, Paul RH , et al. Insulin resistance is associated with cognition among HIV-1-infected patients: the Hawaii Aging With HIV cohort. J Acquir Immune Defic Syndr 2006; 43 (4) 405-410
• 124 Valcour V, Maki P, Bacchetti P , et al. Insulin resistance and cognition among HIV-infected and HIV-uninfected adult women: the Women's Interagency HIV Study. AIDS Res Hum Retroviruses 2012; 28 (5) 447-453
• 125 Wright EJ, Grund B, Robertson K , et al; INSIGHT SMART Study Group. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 2010; 75 (10) 864-873
• 126 Yaldizli O, Kastrup O, Obermann M , et al. Carotid intima-media thickness in HIV-infected individuals: relationship of premature atherosclerosis to neuropsychological deficits?. Eur Neurol 2006; 55 (3) 166-171
• 127 Becker JT, Kingsley L, Mullen J , et al; Multicenter AIDS Cohort Study. Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology 2009; 73 (16) 1292-1299
• 128 Crystal HA, Weedon J, Holman S , et al. Associations of cardiovascular variables and HAART with cognition in middle-aged HIV-infected and uninfected women. J Neurovirol 2011; 17 (5) 469-476
• 129 Fabbiani M, Ciccarelli N, Tana M , et al. Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients. HIV Med 2013; 14 (3) 136-144
• 130 Debette S, Beiser A, DeCarli C , et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke 2010; 41 (4) 600-606
• 131 Kuller LH, Longstreth Jr WT, Arnold AM, Bernick C, Bryan RN, Beauchamp Jr NJ ; Cardiovascular Health Study Collaborative Research Group. White matter hyperintensity on cranial magnetic resonance imaging: a predictor of stroke. Stroke 2004; 35 (8) 1821-1825
• 132 Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MMB ; Rotterdam Scan Study. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003; 34 (5) 1126-1129
• 133 McMurtray A, Nakamoto B, Shikuma C, Valcour V. Small-vessel vascular disease in human immunodeficiency virus infection: the Hawaii aging with HIV cohort study. Cerebrovasc Dis 2007; 24 (2-3) 236-241
• 134 Valcour V, Busovaca E, Wendelken L , et al. Brain white matter lesions link to CVD risk but not HIV factors in HIV over age 60. Paper presented at: 12^th International Symposium on Neurovirology, October 29–November 2, 2013; Washington, DC
• 135 Lavi S, Gaitini D, Milloul V, Jacob G. Impaired cerebral CO₂ vasoreactivity: association with endothelial dysfunction. Am J Physiol Heart Circ Physiol 2006; 291 (4) H1856-H1861
• 136 Brilla R, Nabavi DG, Schulte-Altedorneburg G , et al. Cerebral vasculopathy in HIV infection revealed by transcranial Doppler: A pilot study. Stroke 1999; 30 (4) 811-813
• 137 Tucker KA, Robertson KR, Lin W , et al. Neuroimaging in human immunodeficiency virus infection. J Neuroimmunol 2004; 157 (1-2) 153-162
• 138 Heikinheimo T, Chimbayo D, Kumwenda JJ, Kampondeni S, Allain TJ. Stroke outcomes in Malawi, a country with high prevalence of HIV: a prospective follow-up study. PLoS ONE 2012; 7 (3) e33765
• 139 D'Agostino Sr RB. Cardiovascular risk estimation in 2012: lessons learned and applicability to the HIV population. J Infect Dis 2012; 205 (Suppl. 03) S362-S367
• 140 Schambelan M, Wilson PWF, Yarasheski KE , et al; Working Group 5. Development of appropriate coronary heart disease risk prediction models in HIV-infected patients. Circulation 2008; 118 (2) e48-e53
• 141 Law MG, Friis-Møller N, El-Sadr WM , et al; D:A:D Study Group. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 2006; 7 (4) 218-230
• 142 Friis-Møller N, Thiébaut R, Reiss P , et al; DAD study group. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 2010; 17 (5) 491-501
• 143 Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991; 22 (3) 312-318
• 144 Mateen FJ, Post WS, Sacktor N , et al; Multicenter AIDS Cohort Study (MACS) Investigators. Long-term predictive value of the Framingham Risk Score for Stroke in HIV-positive vs HIV-negative men. Neurology 2013; 81 (24) 2094-2102
• 145 Burkholder GA, Tamhane AR, Salinas JL , et al. Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients. Clin Infect Dis 2012; 55 (11) 1550-1557
• 146 Tornero C, Ventura A, Mafe M. Aspirin is indicated for primary prevention of cardiovascular events in HIV-infected patients. J Acquir Immune Defic Syndr 2010; 54 (5) 560
• 147 Freiberg MS, Leaf DA, Goulet JL , et al. The association between the receipt of lipid lowering therapy and HIV status among veterans who met NCEP/ATP III criteria for the receipt of lipid lowering medication. J Gen Intern Med 2009; 24 (3) 334-340
• 148 Suchindran S, Regan S, Meigs JB , et al. Comparison of aspirin use and incident myocardial infarction rates in HIV-infected and non-HIV-infected patients in a large US health care system. In: Program and Abstracts of the 20^th Conference on Retroviruses and Opportunistic Infections (Atlanta, GA). Alexandria, VA: CROI; 2013
• 149 Silverberg MJ, Leyden W, Hurley L , et al. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med 2009; 150 (5) 301-313
• 150 O'Brien M, Montenont E, Hu L , et al. Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study. J Acquir Immune Defic Syndr 2013; 63 (3) 280-288
• 151 Kolapo KO, Vento S. Stroke: a realistic approach to a growing problem in sub-Saharan Africa is urgently needed. Trop Med Int Health 2011; 16 (6) 707-710
• 152 Ridker PM, Danielson E, Fonseca FAH , et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359 (21) 2195-2207
• 153 Rasmussen LD, Kronborg G, Larsen CS, Pedersen C, Gerstoft J, Obel N. Statin therapy and mortality in HIV-infected individuals; a Danish nationwide population-based cohort study. PLoS ONE 2013; 8 (3) e52828
• 154 Moore RD, Bartlett JG, Gallant JE. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS ONE 2011; 6 (7) e21843
• 155 Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis 2012; 205 (Suppl. 03) S375-S382
• 156 Triant VA. HIV infection and coronary heart disease: an intersection of epidemics. J Infect Dis 2012; 205 (Suppl. 03) S355-S361
• 157 Justice AC, Zingmond DS, Gordon KS , et al; Veterans Aging Cohort Study Project Team. Drug toxicity, HIV progression, or comorbidity of aging: does tipranavir use increase the risk of intracranial hemorrhage?. Clin Infect Dis 2008; 47 (9) 1226-1230